Effects of Multidomain Training of Health With Aging (Train-Old)
NCT05481346, Not applicable, Unknown, Universidad de Almeria
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Multidomain Training of Health With Aging (Train-Old) | ClinicalTrials.gov |
| NCT number | NCT05481346 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 80 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Universidad de Almeria | ClinicalTrials.gov |
| Conditions | Sarcopenia, Memory Loss, Muscular Atrophy, Cardiovascular Diseases, Frailty | ClinicalTrials.gov |
| Interventions | Multidomain training | ClinicalTrials.gov |
| First posted | 2022-08-01 | ClinicalTrials.gov |
| Last updated | 2022-08-02 | ClinicalTrials.gov |
Registered outcomes 21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Body Weight in Kilograms | Change from Baseline body weight (kg) at 18 weeks | was measured after removal of shoes and heavy outer clothing, using a Tanita BC-418 MA or InBody equipment to the nearest 0.1 kg. | ClinicalTrials.gov |
| Primary | Height in Meters | Change from Baseline standing height (cm) at 18 weeks | Standing height without shoes was measured using a Seca 202 stadiometer (Seca, Hamburg, Germany) to the nearest 0.1 cm. | ClinicalTrials.gov |
| Primary | Body Mass Index (BMI) | Change from Baseline Body Mass Index (BMI): (kg/m^2) at 18 weeks | was calculated as the ratio of weight to squared height in kg/m\^2 | ClinicalTrials.gov |
| Primary | % Fat Mass | Change from Baseline bioelectrical impedance % fat mass at 18 weeks | % fat mass was measured after removal of shoes and heavy outer clothing, using a Tanita BC-418 MA or InBody equipment to the nearest 0.1 kg. | ClinicalTrials.gov |
| Primary | Muscle quality sarcopenia | Change from Baseline to 18 weeks | Sarcopenia will be assessed taking into account the reference values established for muscle quality. The muscle quality will be measure by hand grip strength test. This test will be performance with manual dynamometry (TKK 5401; Scientific Instruments Co., Ltd., Tokyo, Japan). Maximal isometric upper limb strength will be performance by maximal isometric strength. Upper strength will be register by kilogrammes. Higher value show high strength. | ClinicalTrials.gov |
| Secondary | Change Blood pressure | Change from Baseline to 18 weeks | Blood pressure and heart rate will be assessed by means of an automatic device (Colin BP 880, Inc., Tampa, FL). This is noninvasive technique. The result will be register in millimeters of mercury (bood pressure) and number of pulse per minutes (heart rate). | ClinicalTrials.gov |
| Secondary | Change Chair stand test | Change from Baseline to 18 weeks | Chair stand test measure the functional capacity. This is a easy physical test. This test measures the functionality of getting up and sitting down from a chair five times. The participant have to performance the test as faster as possible. The total time is recorded in seconds. A better time indicates better functional ability. | ClinicalTrials.gov |
| Secondary | Change Upper and Lower strength | Change from Baseline to 18 weeks | Maximal isometric upper limb strength will be performance by maximal isometric strength of knee extension and biceps flexion with load cell. Maximal isometric lower limb will be registered in newton. Higher value show high strength. | ClinicalTrials.gov |
| Secondary | Health-related quality | Change from Baseline to 18 weeks | SF-36 quality of life questionnaire | ClinicalTrials.gov |
| Secondary | Cardiorrespiratory 6 minutes walk test | Change from Baseline to 18 weeks | cardiorespiratory endurance test that evaluates the distance covered in 6 minutes. | ClinicalTrials.gov |
| Secondary | Change heart rate | Change from Baseline to 18 weeks | Heart rate will be assessed by means of an automatic device (Colin BP 880, Inc., Tampa, FL). This is noninvasive technique. The result will be register in number of pulse per minutes (heart rate). | ClinicalTrials.gov |
| Secondary | Gait speed | Change from Baseline to 18 weeks | Gait speed will be measure by 4. 6 and 10 meter test. This is easy physical test in with the participant have to walk 4. 6 and 10 metres as faster as possible. The result will be register in seconds. Less time indicates better functional ability. | ClinicalTrials.gov |
| Secondary | Time up and go test change | Change from Baseline to 18 weeks | Time up and go test measure the functional capacity of getting up, walking and sitting down form a chair. Participant have to performance this test as faster as possible. This is a easy physical test. Total seconds are records. Less seconds indicates better functional ability. | ClinicalTrials.gov |
| Secondary | Short physical performance battery (SPPB) | Change from Baseline to 18 weeks | Short physical performance battery (SPBB) include three test (balance, chair stand test and gait speed) and report a final score. Chair stand test and gait speed were describe in other outcome. Balance test is a easy physical test. The participant must maintain three balancing positions for 10 seconds to overcome it. Each test offers a different score. Higher score show better functional capacity. | ClinicalTrials.gov |
| Secondary | Fragility | Change from Baseline to 18 weeks | Frailty will be defined in relation to Fried's frailty phenotype (Fried et al., 2001), based on 5 criteria: unintentional weight loss, exhaustion, weakness, slow walking speed and low physical activity. | ClinicalTrials.gov |
| Secondary | Satisfaction with life | Change from Baseline to 18 weeks | The Satisfaction with Life Scale is a 4-item instrument with a Likert-type scale ranging from 1 to 7 points measuring overall subjective happiness by means of statements in which participants rate themselves or compare themselves with others. Two items ask people to describe themselves using absolute rating criteria of their lives or rating criteria with respect to others, while the other two items present brief descriptions of happy or unhappy people and respondents are asked to indicate the degree to which they identify with that description. | ClinicalTrials.gov |
| Secondary | Depression | Change from Baseline to 18 weeks | Depression will be measured through the Center for Epidemiological Studies Depression Scale-Revised (CESD-R) (Van Dam \& Earleywine, 2011), is a 20-item questionnaire that can be used to measure levels of depressive symptoms among elderly participants. The CESD-R consists of 16 items of negative affect and 4 items of positive affect. | ClinicalTrials.gov |
| Secondary | Cognitive flexibility | Change from Baseline to 18 weeks | the Stroop test measures the ability to classify information selectively. It consists of 3 phases and requires discerning between colors and words without making mistakes. | ClinicalTrials.gov |
| Secondary | Attention test | Change from Baseline to 18 weeks | the Trail Making test will also assess flexibility of thought and visuospatial ability. It consists of joining numbers and words in a numerical sequence without error. | ClinicalTrials.gov |
| Secondary | PSQ test | Change from Baseline to 18 weeks | To evaluate the factors that influence the general state of health, specifically stress. It evaluates six factors: Tension-Instability-Fatigue; Social Acceptance of Conflict; Energy and Fun; Overload; Satisfaction for self-fulfillment; Fear and anxiety. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)